adenoviridae vector ChAdOx1 can be used to make vaccinations that are protective against Middle East Respiratory Syndrome (MERS) in mice and able to... 12 KB (1,134 words) - 21:49, 25 March 2024 |
 | respiratory syndrome (MERS) is a viral respiratory infection caused by Middle East respiratory syndrome–related coronavirus (MERS-CoV). Symptoms may range... 86 KB (7,259 words) - 11:02, 11 April 2024 |
 | the adenoviral vector ChAdOx1 can be used to make vaccinations that are protective against Middle East respiratory syndrome (MERS) in mice and able to... 26 KB (2,706 words) - 19:36, 11 December 2023 |
COVID-19 vaccine (category Articles without InChI source) viral-vectored vaccines: two adenoviral-vectored (ChAdOx1-MERS, BVRS-GamVac) and one MVA-vectored (MVA-MERS-S). Vaccines that use an inactive or weakened... 192 KB (21,930 words) - 19:29, 15 April 2024 |
 | as the primary treatment approach. In January 2024 a candidate vaccine, ChAdOx1 NipahB, commenced Phase I clinical trials after completing laboratory and... 22 KB (2,282 words) - 23:40, 9 March 2024 |
 | PMID 24530395. Orexin receptor subtypes readily formed homo- and hetero(di)mers, as suggested by significant BRET signals. CB1 receptors formed homodimers... 67 KB (7,707 words) - 01:59, 28 March 2024 |
production of the ChAdOx1 nCoV-19 vaccination. The team started research in January 2020, and managed to identify a chimpanzee adenovirus vector (ChAdOx) that generated... 13 KB (1,233 words) - 04:04, 7 April 2024 |
 | Pfizer–BioNTech COVID-19 vaccine (category Articles without InChI source) 7% against delta, similar to effectiveness provided by one dose of the ChAdOx1 nCoV-19 vaccine. On 27 August, the U.S. Centers for Disease Control and... 236 KB (19,394 words) - 05:58, 20 April 2024 |
 | Sputnik V COVID-19 vaccine (category Articles without InChI source) the Oxford–AstraZeneca COVID‑19 vaccine, uses chimpanzee adenovirus (ChAdOx1) as the vector. For both the Oxford-AstraZeneca COVID-19 and Gam-COVID-Vac... 154 KB (13,880 words) - 13:52, 20 April 2024 |
 | March 2021. "WHO Recommendation AstraZeneca/SKBio - COVID-19 Vaccine (ChAdOx1-S [recombinant])". World Health Organization (WHO). 15 February 2021. Archived... 118 KB (12,634 words) - 14:17, 25 January 2024 |
distributed 28 days apart. The trials involved participants either receiving the ChAdOx1 nCoV-19 vaccine or a control substance like saline. The efficiency results... 76 KB (9,806 words) - 09:53, 22 April 2024 |